GleamWall
中文EN

ANRO Alto Neuroscience, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1999480 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-52.9%
TTM EPS YoY-0.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-46.6%
ROA-40.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.05x
Current ratio18.12x
Interest coverage-48.48x

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$18.16M$22.11M$20.29M$12.00M$10.53M$13.12M$9.97M$10.80M
SG&A expense$9.06M$7.02M$6.84M$5.06M$4.43M$5.56M$5.70M$6.20M
Operating income-$27.23M-$29.13M-$27.14M-$17.05M-$14.95M-$18.68M-$15.68M-$17.00M
Interest expense$463,000$491,000$545,000$575,000$650,000$646,000$598,000$333,000
Income tax———$0$0$0$0$0
Net income-$25.12M-$27.64M-$26.24M-$16.18M-$14.18M-$17.71M-$15.17M-$15.20M
EBITDA-$27.12M-$28.93M-$26.95M-$16.90M-$14.75M-$18.58M-$15.51M-$16.83M
EPS (basic)-0.54-0.65-0.80—-0.52-0.65-0.56—
EPS (diluted)-0.54-0.65-0.80—-0.52-0.65-0.56—
Weighted avg. shares (diluted)46.53M42.81M32.89M—27.10M27.07M27.05M—
Balance sheet
Cash & equivalents$319.34M$243.73M$263.76M$176.48M$138.32M$148.09M$161.25M$168.73M
Current assets$323.20M$247.32M$269.13M$177.72M$139.45M$149.85M$163.52M$169.34M
PP&E, net$1.87M$2.05M$2.23M$1.87M$2.03M$2.31M$2.48M$2.67M
Total assets$326.50M$254.07M$276.26M$184.69M$147.01M$157.88M$171.91M$177.54M
Current liabilities$17.84M$16.65M$13.12M$11.32M$9.04M$8.13M$7.26M$10.01M
Short-term debt$4.51M$3.77M$2.14M$585,000———$0
Long-term debt$8.97M$12.42M$13.88M$16.17M$20.31M$20.12M$19.94M$10.25M
Total debt$13.48M$16.19M$16.02M$16.76M$20.31M$20.12M$19.94M$10.25M
Total liabilities$29.98M$34.82M$32.89M$33.55M$35.45M$34.47M$32.82M$26.08M
Shareholders' equity$296.53M$219.25M$243.37M$151.14M$111.56M$123.41M$139.10M$151.46M
Net debt-$305.86M-$227.55M-$247.74M-$159.73M-$118.00M-$127.96M-$141.31M-$158.47M
Shares outstanding39.98M35.09M35.05M31.92M27.17M27.07M27.07M26.99M
Cash flow statement
Operating cash flow-$20.76M-$19.76M-$27.09M-$11.52M-$9.92M-$13.78M-$16.56M-$13.02M
Capital expenditure$0$0$556,000$0$0$0$24,000$506,000
Free cash flow-$20.76M-$19.76M-$27.65M-$11.52M-$9.92M-$13.78M-$16.58M-$13.53M
Investing cash flow$0$0-$556,000$0$0$0-$24,000-$506,000
Financing cash flow$96.36M-$273,000$114.94M$50.19M$153,000$613,000$9.13M$49,000
Depreciation & amortization$100,000$200,000$184,000$157,000$200,000$100,000$171,000$170,000
Stock-based compensation$3.52M$3.55M$2.82M$1.95M$2.19M$2.00M$1.97M$1.57M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.